Skip to main content
ARS Home » Research » Publications at this Location » Publication #334348
Title: Adenovirus-vectored foot-and-mouth disease vaccine confers early and full protection against FMDV O1 Manisa in swine

Author
item FERNANDEZ SAINZ, IGNACIO - University Of Connecticut
item MEDINA, GISSELLE - Oak Ridge Institute For Science And Education (ORISE)
item RAMIREZ, ELIZABETH - Oak Ridge Institute For Science And Education (ORISE)
item KOSTER, MARLA - Former ARS Employee
item GRUBMAN, MARVIN - Former ARS Employee
item De Los Santos, Teresa

Submitted to: Virology
Publication Type: Peer Reviewed Journal
Publication Acceptance Date: 12/19/2016
Publication Date: N/A
Citation: N/A

Interpretive Summary: We have previously shown that a human adenovirus (Ad5) vectored foot-and-mouth disease virus vaccine (Ad5-FMD) could protect swine and cattle against foot and mouth disease virus (FMDV) of A24 serotype. Here we show that a similar approach is effective against FMDV O1-Manisa, another FMDV type of relevance mostly in Asia and the Middle East. It has been demonstrated that current inactivated virus vaccines against O1Manisa are or could be used in these areas to protect animals such as swine, sheep and cattle against many circulating subtypes of the FMDV O1 lineage. Our studies show that swine inoculated with relative low doses of Ad5-O1Man developed a strong immune response and can be fully protected against challenge with FMDV at 7 and 21 days post vaccination. Interestingly, these animals developed an antibody response that cross-reacts with FMDV strains that caused recent outbreaks such as the UK 2001 or South Korea 2010.

Technical Abstract: A human adenovirus (Ad5) vectored foot-and-mouth disease virus (FMDV) sero-type O1-Manisa subunit vaccine (Ad5-O1Man) was engineered to deliver FMDV O1-Manisa empty capsids. Swine inoculated with Ad5-O1Man developed an FMDV-specific neutralizing antibody response as compared to animals inoculated with the original empty vector and were completely protected against homologous challenge either at 7 or 21 days post-vaccination (dpv). Potency studies exhibited a PD50 of about 107 pfu/animal and, in independent experiments, a dose of 4x107pfu/animal fully protected swine against intradermal challenge with FMDV. In-vitro cross-neutralization analysis distinctly predicted that swine vaccinated with Ad5-O1Man would be protected against challenge with homologous FMDV O1M and recent outbreak strains of Mya-98 South East Asia (SEA) lineage including O1-UK2001 and O1-Korea2010. These results indicate that the recombinant Ad5-O1Man is an effective, safe and cross-reacting vaccine and can be used preventively and in outbreak situations to control FMD O Mya-98 lineage viruses in swine.